Katana VentraIP

Sinopharm WIBP COVID-19 vaccine

The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV,[1][2] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group).[3] The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.

For other uses, see Sinopharm COVID-19 vaccine.

Vaccine description

SARS-CoV-2

Inactivated

Zhongkangkewei (Chinese: 众康可维)

Intramuscular

  • None

  • Full and emergency authorizations
Full list of Sinopharm WIBP authorizations

Manufacturing[edit]

In June 2021, a new factory started production with the capacity to manufacture 1 billion doses annually.[7]